Only low price in drug bidding is named

Source: saibelan 2018-01-29 according to the latest news that saibelan learned, at the Symposium of the State Council's Medical Reform Office held on 23, relevant departments asked for opinions on rectifying the provincial drug bidding platform, and it is expected that there will be a major change in drug centralized procurement Among them, only the low price of drug bidding is named Coincidentally, on January 27, Gao Zhenkun, general manager of Beijing Tongrentang Co., Ltd., expressed similar opinions It seems that low price is really a pain in the hearts of many medical people! On January 27, Gao Zhenkun, general manager of Beijing Tongrentang Co., Ltd., revealed to the media that at present, there is a phenomenon of "price only" in the list of Medicare drugs when increasing the types of drugs, and many high-cost high-quality drugs and brand enterprises are difficult to enter it ▍ the only objection to low price is that there is a media comment that in China's drug market, even some experts in the industry can't figure out how much water there is in the drug price because there is no open and conclusive data The drug price has always been a grey area unknown to people outside the industry On the one hand, the drug price is a gray area for many people, on the other hand, for drugs, it is often only the price The real price of drugs is unknown, but only the price is taken, which is controversial During the group meeting of the first session of the 15th National People's Congress of Beijing, Gao Zhenkun suggested to the media that more drugs with price files should be added to the medical insurance catalogue for patients to choose during the updating process, and high-quality drugs with high price can be included in the medical insurance scope in the form of partial medical insurance reimbursement In addition, Gao Zhenkun also said that "with the acceleration of the new medical reform, in addition to the update of the medical insurance catalog, there is also a situation of too low price in the drug sunshine bidding procurement, which affects the patients' choice of drugs." In fact, it is not the first time that the anti drug price only theory was mentioned during the National People's Congress Many experts in the industry have expressed similar opinions before "Now the mainstream media are still talking about the false high drug prices I don't think this can be generalized We need to fully investigate what kind of high and what kind of low drug prices are." Zhang Boli, academician of the Chinese Academy of engineering and President of Tianjin University of traditional Chinese medicine, said Zhang Boli mentioned in the proposal that centralized drug purchase must be standardized, not only low but medium He suggested that the formation mechanism and method of drug price should be formulated and the third-party monitoring should be carried out Guan Yanbin, chairman of sunflower Pharmaceutical Co., Ltd., also believes that it is necessary to support the development of national pharmaceutical industry in policy orientation If all drugs are subject to price scale bidding, few enterprises will take risks to innovate According to Guan Yanbin, the price only bidding system is harmful to national industry and should be corrected thoroughly The only way to break the corruption in the medical field is by means of marketization In the proposal, Huabei pharmaceutical group suggested that drug prices should be set on the basis of social average cost, taking into account the cost changes, inflation and other factors caused by economic cyclical fluctuations, so as to ensure that the enterprise's period expense rate is not less than 30%, and the sales profit rate is not less than 15% Zhang Bin, a director of Dongsheng Group, also said that the only way to get drugs at a low price only considered the cost of raw materials of drugs, regardless of the cost of research and development and innovation, which is not conducive to the reform of drug prices and may cause a shortage of classic drugs ▍ the complaint that the drug price is too high to squeeze water is not only from people outside the industry, many people in the industry also think that the drug price is too high to squeeze out space Yang Baofeng, President of Harbin Medical University and academician of Chinese Academy of engineering, gave an example at the first high-end forum of implementing health China strategy - development of health industry attended by Cyprian blue on January 27 As a researcher, the purpose of researching new drugs is to benefit mankind However, his research results, which cost no more than 3 yuan, were priced at 598 yuan by the manufacturer after successful transformation, which he felt helpless From the perspective of manufacturers, they often think that a drug needs a long research and development cycle, and high pricing can successfully recover costs At the previous national "two sessions", Wei Feiyan, chairman of Guangxi Huahong Pharmaceutical Co., Ltd., once claimed that 90% of the drugs had room for price reduction, and there was no problem in cutting half the price Prior to that, cypress blue also reported some information about the soaring drug prices caused by monopoly of individual manufacturers Some insiders do believe that the monopoly of interest groups leads to the inflated price of drugs They said that the pharmaceutical companies with the highest sales often occupy a monopoly position in the top three hospitals, and they also have a greater say in the price of drugs ▍ we should focus on what kind of medicine we want to squeeze We are against the idea that low prices are the only way to get water We are against the idea that the price of medicine is too high We should squeeze water On the surface, the opinions of the two groups are almost contradictory But by referring to the sunshine procurement practice of Beijing health and Family Planning Commission, we may be able to understand the differences Beijing Municipal Commission of health and family planning told the media that sunshine purchasing does not mean that all drugs are reduced in price The specific method of sunshine purchasing in Beijing is to divide the drugs into three categories to determine the price For the commonly used drugs with sufficient market supply and sufficient competition, we will dynamically link the centralized purchase prices of drugs at all provincial levels across the country, further reduce the false high prices of drugs, and guide the prices of the same kind of drugs in Beijing to remain at a lower level throughout the country In the case of short supply of drugs, we should put the guarantee of clinical drug supply in the first place, and reasonably raise the price of drugs, especially the national and regional shortage of drugs, so as to effectively occupy the market and purchase the first opportunity in the case of shortage of goods, and at the same time, promote the active production of enterprises In addition, in accordance with the relevant national policies, enterprises are encouraged to produce more and use more low-cost drugs in clinical practice, so as to reduce the total cost of medical treatment In order to avoid the delisting risk of cheap drugs, medical institutions consult the actual supply prices of surrounding provinces and cities, and negotiate with production enterprises to form the supply prices For some high-quality brand Chinese patent medicines, in view of the rising price of raw materials year by year, the price of drugs will be increased That is to say, the drug price is not empty but high, so it cannot be generalized Methods for different drugs can not be generalized For the high drug price and the water content to be squeezed, the relevant departments must squeeze However, it is not only the low price, but also the "good currency" and the drugs in short supply in the market The policy will also have different price protection In general, for different types of drugs, more refined bidding procurement should be the general direction of the policy